Eltrombopag To Reduce The Need For Platelet Transfusion In Subjects With Chronic Liver Disease And Thrombocytopenia Undergoing Elective Invasive Procedures

Inclusion Criteria: * Male and female subjects, 18 years of age or more with chronic liver disease. * Child-Pugh score of 12 or less. * Model of End Stage Liver Disease (MELD) score of 24 or less. * Subjects who, in the opinion of the investigator, are appropriate candidates to undergo an elective invasive procedure and who require a platelet transfusion to manage the risk of bleeding associated with the procedure. * A baseline platelet count \<50,000/µL. * A baseline serum sodium level \>130mEq/L. * Haemoglobin concentration \>8g/dL stable for at least one month. * A female is eligible to enter and participate in the study if she is of: Non-childbearing potential (i.e., physiologically incapable of becoming pregnant) including any female who: * Has had a hysterectomy * Has had a bilateral oophorectomy (ovariectomy) * Has had a bilateral tubal ligation * Is post-menopausal (demonstrate total cessation of menses for greater than one year) Childbearing potential, has a negative urine and/or serum pregnancy test at screening, and within the 24 hour period prior to the first dose of investigational product and uses one of the following acceptable methods of contraception: * Complete abstinence from intercourse for two weeks before exposure to the study drug, throughout the clinical study, and for 28 days after completion or premature discontinuation from the study to account for the elimination of the study drug (minimum of 5 half-lives). * Any intrauterine device (IUD) with…